7 completed, 7 terminated, 6 unknown, 5 active not recruiting. 18 Phase 2, 4 Phase 1, 3 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Chronic Graft-versus-host-disease: new trials by email Literature Review of Chronic Graft-versus-host-disease trials Research Report on Chronic Graft-versus-host-disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD INCA034176 - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 32 | 2025-06-25 | 2026-08-10 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Corporation | 9 | 2025-06-04 | 2026-08-25 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease INCA034176, Placebo, Corticosteroids - Chronic Graft-versus-host-disease | Phase 3 | Recruiting | Incyte Corporation | 240 | 2025-01-21 | 2026-10-09 |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Axatilimab, Ruxolitinib, Corticosteroids - Chronic Graft-versus-host-disease | Phase 2 | Active not recruiting | Incyte Corporation | 130 | 2024-10-11 | 2026-10-15 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease INCA034176 - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Biosciences Japan GK | 21 | 2024-07-30 | 2026-10-05 |
| Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201) Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation | Unknown | University of British Columbia | 320 | 2023-07-01 | 2023-12-08 | |
| The Association of Microbiota Composition With cGVHD After Allo-HSCT blood sample, stool sample - Hematopoietic Stem Cell Transplantation, Hematologic Malignancy | Unknown | First Affiliated Hospital of Zhejiang University | 300 | 2022-05-01 | 2022-08-02 | |
| Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial Exercise, Attention control - Graft Vs Host Disease, Acute-graft-versus-host Disease | Not applicable | Recruiting | Dana-Farber Cancer Institute | 36 | 2022-04-14 | 2026-03-11 |
| Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease Low-dose ibrutinib - Chronic Graft-versus-host-disease | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 13 | 2022-04-01 | 2022-04-27 |
| Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 Belumosudil 200 mg QD, Belumosudil 200 mg BID, Belumosudil 400 mg QD - Chronic Graft-versus-host-disease | Phase 2 | Completed | Kadmon, a Sanofi Company | 23 | 2022-02-23 | 2025-05-02 |
| Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease Ruxolitinib - Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 13 | 2021-10-27 | 2024-01-16 |
| A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) Axatilimab - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Syndax Pharmaceuticals | 296 | 2021-03-04 | 2026-06-16 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Itacitinib, Extracorporeal Photopheresis (ECP) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | University of Utah | 3 | 2021-01-29 | 2024-01-22 |
| Dexamethasone Solution and Dexamethasone in Mucolox™ dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™ - Oral Lichen Planus, Mucous Membrane Pemphigoid | Phase 2 | Completed | University of California, San Francisco | 29 | 2020-12-26 | 2023-12-15 |
| Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study Chronic Graft-versus-Host-Disease, Leukemia | Unknown | University of British Columbia | 350 | 2020-11-15 | 2023-12-05 | |
| ATG Plus PTCy vs ATG for CGVHD Prophylaxis Cyclophosphamide, Anti-Thymocyte globulin (rabbit) - Acute Leukemia, Myelodysplasia | Phase 2 | Active not recruiting | McMaster University | 80 | 2020-10-14 | 2025-05-11 |
| A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Itacitinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | SCRI Development Innovations, LLC | 15 | 2020-06-05 | 2024-11-06 |
| Anlotinib Treatment in Steroid Depenent/Refractory cGVHD Anlotinib - Chronic Graft-versus-host-disease | Phase 2 | Terminated | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 5 | 2020-04-10 | 2021-03-24 |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) Acalabrutinib 2x100 MG Oral Capsule + alloSCT - Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease | Phase 2 | Completed | Polish Lymphoma Research Group | 29 | 2019-08-19 | 2025-01-16 |
Showing 20 of 29. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (29) · Graft vs Host Disease (3) · Hematologic Neoplasms (3) · Leukemia (2) · Anemia, Refractory, with Excess of Blasts (1) · Cytokine Release Syndrome (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lichen Planus, Oral (1) · Lymphoma, Mantle-Cell (1) · Neoplasm, Residual (1) · Neoplasms (1) · Pemphigoid, Benign Mucous Membrane (1) · Pemphigus (1)
Bronchial Diseases (29) · Bronchiolitis (29) · Bronchiolitis Obliterans (29) · Bronchitis (29) · Immune System Diseases (29) · Lung Diseases (29) · Lung Diseases, Obstructive (29) · Organizing Pneumonia (29) · Respiratory Tract Diseases (29) · Graft vs Host Disease (26) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms (4) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3)
axatilimab (8) · Photopheresis (4) · ibrutinib (4) · Rituximab (3) · Sirolimus (3) · Adrenal Cortex Hormones (2) · Blood Specimen Collection (2) · Calcineurin Inhibitors (2) · Cyclosporine (2) · Everolimus (2) · Imatinib Mesylate (2) · Methylprednisolone (2) · Mycophenolic Acid (2) · Prednisolone (2) · Prednisone (2)
Incyte Corporation (5) · Dana-Farber Cancer Institute (3) · Kadmon, a Sanofi Company (2) · Syndax Pharmaceuticals (2) · University of British Columbia (2) · Children's Hospital Medical Center, Cincinnati (1) · Dartmouth-Hitchcock Medical Center (1) · First Affiliated Hospital of Zhejiang University (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Incyte Biosciences Japan GK (1) · Masonic Cancer Center, University of Minnesota (1) · McMaster University (1) · National Cancer Institute (NCI) (1) · Polish Lymphoma Research Group (1) · SCM Lifescience Co., LTD. (1)
United States (19) · Canada (6) · Germany (5) · Italy (5) · Spain (5) · United Kingdom (5) · Belgium (4) · Australia (3) · China (3) · France (3) · Austria (2) · Greece (2) · Ireland (2) · Japan (2) · Netherlands (2)
Albert Assad, MD (1) · Alessandro Villa, DDS, PhD, MPH (1) · Andrew C Harris, MD (1) · Bingyi Wu, MD (1) · Catherine Lee, MD (1) · Christina Dieli-Conwright (1) · Ellen Hooper, M.D. (1) · Irwin R Walker, MBBS (1) · John Koreth, MBBS,D.Phil (1) · John M Hill, MD (1) · Kirk R Schultz, MD (1) · Kirk R. Schultz, MD (1) · Kristjan Paulson, MD (1)
PMID 39704205, PMID 30936057, PMID 31260802, PMID 31664782, PMID 34265047, PMID 35781099, PMID 36459673, PMID 37549933, PMID 39292927, PMID 40311075, PMID 42629427
2023 (1)